北京若生智能科技有限公司
Drug Database
DO

doxorubicin hydrochloride (Libod / Libaoduo)

✓ Approved

Shanghai Fudan-Zhangjiang · TOP2A · 小分子

什么是 doxorubicin hydrochloride？

doxorubicin hydrochloride 是一种小分子，由Shanghai Fudan-Zhangjiang研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Libod, Libaoduo
公司Shanghai Fudan-Zhangjiang
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Shanghai Fudan-Zhangjiang

作用机制

分子靶点

doxorubicin hydrochloride 作用于 1 个分子靶点：

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

doxorubicin hydrochloride 针对 4 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedRSC pharmaceutics2026-09-10

Phosphatidylserine-based liposomes encapsulating DMX-5804 protect against doxorubicin-induced cardiotoxicity.

Tetterton-Kellner Jessica J, Miserendino Audreanna A, Tariq Imran I, Jensen Brian C BC et al.

Anthracycline induced cardiotoxicity is a significant problem for oncologists and cancer patients. The leading cause of non-cancer death in cancer patients and survivors is heart failure, which is frequently attributed to the exposure to chemotherapeutics like anthracyclines. The most notorious of these chemotherapeutics is doxorubicin, which causes cardiac contractile dysfunction, which in some cases is irreversible. In this study, we report the development of NanoDMX, a phosphatidylserine-containing liposomal formulation of DMX5804, a small molecule inhibitor of MAP4K4, and demonstrate that its administration prevents doxorubicin-induced left ventricular dysfunction in mice. Additionally, we demonstrate that DMX-5804 protects cardiomyocytes in vitro through a combination of mechanisms outside of the expected route of suppressing the JNK pathway. Overall, we demonstrate that the use of NanoDMX, a novel liposomal system using both DMX-5804 and phosphatidylserine, can prevent the damage induced by doxorubicin over the course of a single high dose in vivo model.

PMID 42719253
阅读全文 →
PubMedTherapeutic advances in hematology2026-09-10

Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report.

Wei Yuhui Y, Yang Xuejiao X, Zheng Yulan Y, Zhang Dongdong D

Multiple myeloma (MM) is a plasma cell malignancy that typically follows a protracted clinical course. Extramedullary disease (EMD) represents an aggressive manifestation of MM with a relatively low incidence, traditionally involving the skin and soft tissues. While MM usually progresses indolently, fulminant disease progression characterized by extensive multivisceral and vascular infiltration is exceptionally rare and seldom documented in the medical literature. This case illustrates a 64-year-old woman who presented with left chest wall mass and pain and was diagnosed with high-risk IgG-λ-type MM (R-ISS Stage II), harboring 1q21 amplification and IGH/FGFR3 translocation. Following 12 cycles of VCD (bortezomib, cyclophosphamide, and dexamethasone) induction, she achieved partial remission and proceeded to maintenance therapy with bortezomib and ixazomib. Fifteen months post-diagnosis, the patient presented with a rapidly enlarging abdominal wall mass. 18F-FDG PET-CT revealed widespread hypermetabolic activity involving the heart, major blood vessels, liver, spleen, lungs, and multiple soft tissue sites, indicating extensive EMD. Bone marrow examination showed only 1% plasma cells, demonstrating a marked dissociation between systemic EMD and medullary involvement. Despite salvage therapy with carfilzomib, liposomal doxorubicin, and dexamethasone, the patient's condition deteriorated rapidly. Compounded by severe hypoproteinemia, electrolyte disturbances, and respiratory infection, the disease followed a fulminant course, ultimately leading to the patient's death. This case represents a catastrophic transition of genetically high-risk MM from initial medullary involvement to widespread multivisceral and cardiovascular infiltration upon relapse. It highlights a rare phenotype of relapsed/refractory MM where aggressive extramedullary proliferation occurs independently of bone marrow progression. Such patients face a dismal prognosis and present a formidable challenge for current salvage therapeutic strategies.

PMID 42719364
阅读全文 →
PubMedFrontiers in bioengineering and biotechnology2026-09-10

Verbascoside-rich Buddleja davidii extract in liposomal systems: modulation of release behavior for topical wound treatment.

Yasmin Adeela A, Casula Luca L, Pittiu Alessio A, Massoni Claudia C et al.

Introduction: Chronic wounds represent a major clinical challenge due to their complex pathophysiology, characterized by persistent inflammation, excessive production of reactive oxygen species (ROS), high risk of microbial contamination, and impaired tissue regeneration. Despite several plant extracts offering antioxidant, anti-inflammatory, and antibacterial properties, their therapeutic use is limited by poor stability and rapid clearance of the active compounds from the wound site, particularly in the case of hydrophilic molecules. In this study, a verbascoside-rich extract obtained from Buddleja davidii was encapsulated into liposomes for potential wound healing applications. Methods: The formulations were characterized in terms of vesicle size, polydispersity index, and zeta potential using dynamic and electrophoretic light scattering. Encapsulation efficiency and verbascoside release profiles were assessed by HPLC, while antioxidant activity was evaluated by the DPPH assay. Formulation stability was monitored for two months, and in vitro biocompatibility and antioxidant protective effects were investigated in human keratinocytes, while antimicrobial activity was tested against methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. Results: The liposomal formulations modulated the release kinetics of verbascoside, showing a prolonged release of the encapsulated fraction, limiting its rapid dispersion in aqueous environments and enabling sustained availability over time. Encapsulation preserved the antioxidant activity of the extract and ensured excellent in vitro biocompatibility across a wide concentration range. Finally, liposomes showed strong and concentration-dependent antimicrobial activity against MRSA, as well as bacteriostatic responses against E. coli. Discussion: Collectively, these findings highlight liposomal encapsulation as a solid strategy to prolong the release-and thus the residence time-of hydrophilic plant-derived actives while maintaining or potentiating their biological activities in the context of wound healing.

PMID 42718759
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-09-10

Manipulating the Buried Interfacial Dipole: The Role of Pyridine Acetate-Hydrochloride Isomers in Carbon-Based Perovskite Solar Cells Prepared in Air.

Shi Yifei Y, Gong Jianwen J, Wang Xu X, Hu Shuming S et al.

The buried interface between tin oxide and perovskite is the key factor for non-radiative recombination and energy level mismatch, which limits the performance and stability of perovskite solar cells. This work explores a simple interfacial dipole engineering strategy, where three pyridine acetate-hydrochloride (PAH) isomer molecules (2-PAH, 3-PAH, and 4-PAH) are used to modify the SnO2 electron transport layer. The 3-PAH-modified layer can control the work function of tin oxide, achieve the best energy level alignment, and improve the crystallization quality of the perovskite film, thereby effectively suppressing interface recombination and promoting electron extraction. All the devices are prepared in air, and the device optimized by 3-PAH achieved a champion energy conversion efficiency of 14.31% and demonstrated stability. Subsequent to an 800 h placement in an N2 glove box or a 340 h exposure to an air environment, the unencapsulated target devices that were modified by 3-PAH maintained 80.7% and 81.3% of their initial efficiency.

PMID 42717680
阅读全文 →
PubMedAAPS PharmSciTech2026-09-10

Ethosomal Gel-Based Topical Delivery of Albendazole Hydrochloride for Psoriasis: In Vitro and In Vivo Evaluation.

Rençber Seda S, Karpuz Merve M, Ünlü Çakıcı Büşra B, Karayıldırım Çinel Köksal ÇK et al.

This study aimed to develop an albendazole hydrochloride (ALB)-loaded ethosomal gel for topical psoriasis treatment. ALB-loaded ethosomes were prepared and characterized to select the optimal formulation, which was subsequently incorporated into an HPMC-based hydrogel. The ethosomal gel was evaluated through physicochemical, in vitro and in vivo studies. The optimized ethosomal formulation prepared by the film hydration method exhibited a mean vesicle size of 490.00 ± 0.14 nm, polydispersity index of 0.31 ± 0.14, zeta potential of -22.85 ± 2.28 mV and encapsulation efficiency of 23.90 ± 1.43%. After incorporation into the hydrogel matrix, the Gel4-E3/ALB formulation demonstrated appropriate mechanical properties (hardness 8.42 ± 0.70 mN, adhesiveness - 16.85 ± 1.50 mN·s, elasticity 0.89 ± 0.07, cohesiveness 1.14 ± 0.09) and shear-thinning behavior, ensuring ease of application and skin retention. A controlled release pattern was observed, consistent with the controlled-release behavior expected from ethosomal hydrogel systems. Radiolabeling studies demonstrated high labeling efficiency (> 95%). In vitro cytotoxicity evaluation indicated that the optimized ethosomal gel formulation was non-toxic. In vivo studies performed in an imiquimod (IMQ)-induced psoriatic mouse model revealed significant therapeutic improvement in the Gel4-E3/ALB-treated group compared with the IMQ control, with visible reduction in erythema, scaling, and skin thickening after the fifth day of treatment. Hematological analysis showed no adverse effects associated with the formulation. Histopathological evaluation confirmed the reduction in epidermal hyperplasia and inflammatory cell infiltration in the treated group. The developed ALB-loaded ethosomal gel represents a safe and promising topical therapeutic system for psoriasis management.

PMID 42717176
阅读全文 →
PubMedFrontiers in medicine2026-09-10

A case report of Emergomyces orientalis infection in the lung of HIV infected in patient and literature review.

Luo Lifeng L, Guo Ying Y, Nie Zunzhen Z

This study reports a rare case of pulmonary Emergomyces orientalis infection with clinical characteristics, diagnostic approaches and therapeutic regimens of this rare fungal infection, aiming to provide evidence for clinical diagnosis and management. We retrospectively analyzed the patient's clinical symptoms, imaging manifestations, laboratory examinations including metagenomic next-generation sequencing (mNGS), diagnostic and therapeutic procedures, as well as prognosis. Related published literature was searched, reviewed and summarized. The patient presented with a 3-day cough and expectoration. Conventional pathogen examinations showed the patient is infected with the HIV virus and definite diagnosis of Emergomyces orientalis infection was finally confirmed by mNGS of lung biopsy specimens. He received liposomal amphotericin B combined with symptomatic supportive therapy. Clinical symptoms were alleviated and pulmonary lesions were absorbed after treatment. Pulmonary Emergomyces orientalis infection is uncommon and prone to missed diagnosis and misdiagnosis with high mortality. Routine pathogen culture yields a low positive rate. mNGS serves as a critical tool for early and accurate diagnosis. Individualized antifungal treatment, strict drug interaction assessment and therapeutic monitoring are essential to optimize clinical prognosis.

PMID 42719226
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxorubicin hydrochloride